-
Posted by
Two Blokes Jun 20 -
Filed in
Stock
-
6 views
Earlier this week, Sarepta Therapeutics, Inc SRPT provided a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-ambulatory patients.
